{
    "id": 520,
    "fullName": "IGF1R wild-type",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "Wild-type IGF1R indicates that no mutation has been detected within the IGF1R gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 3480,
        "geneSymbol": "IGF1R",
        "terms": [
            "IGF1R",
            "CD221",
            "IGFIR",
            "IGFR",
            "JTK13"
        ]
    },
    "variant": "wild-type",
    "createDate": "05/13/2014",
    "updateDate": "08/28/2017",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 1139,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD3463 was shown to inhibit IGF1R in multiple cancer cell lines, demonstrating antiproliferative activity in culture (Cancer Research: April 15, 2013; Volume 73, Issue 8, Supplement, Abstract #919).",
            "molecularProfile": {
                "id": 578,
                "profileName": "IGF1R wild-type"
            },
            "therapy": {
                "id": 1586,
                "therapyName": "AZD3463",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 882,
                    "pubMedId": null,
                    "title": "Abstract 919: AZD3463, a novel ALK/IGF1R inhibitor, overcomes multiple mechanisms of acquired resistance to crizotinib.",
                    "url": "http://cancerres.aacrjournals.org/content/73/8_Supplement/919.abstract"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3976,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, glioma cells were sensitive to TAE226 in culture and in cell line xenograft models, resulting in inhibition of both Igf-1r phosphorylation and downstream signaling and an improved survival rate (PMID: 17431114).",
            "molecularProfile": {
                "id": 578,
                "profileName": "IGF1R wild-type"
            },
            "therapy": {
                "id": 2086,
                "therapyName": "TAE226",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 1918,
                    "pubMedId": 17431114,
                    "title": "Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17431114"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1147,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Linsitinib (OSI-906) was shown to inhibit proliferation in a variety of tumor cell lines and demonstrated anti-tumor activity in an IGF-1R-driven LISN xenograft model (PMID: 21425998).",
            "molecularProfile": {
                "id": 578,
                "profileName": "IGF1R wild-type"
            },
            "therapy": {
                "id": 798,
                "therapyName": "Linsitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 887,
                    "pubMedId": 21425998,
                    "title": "Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21425998"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 578,
            "profileName": "IGF1R wild-type",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}